跳至主要内容
临床试验/JPRN-jRCT1080222534
JPRN-jRCT1080222534已完成4 期

Phase IV clinical trial of TO-194SL -Evaluation of long-term efficacy and safety in patients with Japanese cedar pollinosis

Torii Pharmaceutical Co., Ltd.0 个研究点目标入组 233 人开始时间: 2014年6月18日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
233

研究概览

简要总结

JC pollen SLIT drops demonstrated treatment duration-dependent efficacy with effects that persisted for 2 years after cessation of treatment. The drug had a favorable safety profile over the 5-year study period.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 12age old 至 <= 64age old(—)
性别
All

入选标准

  • 1)Patients with specific IgE against cedar pollen : class 3 or more.
  • 2)Patients who have a clinical history of cedar pollinosis in 2013 and 2014 cedar pollen seasons.

排除标准

  • 1)Patients with perennial allergic rhinitis, medication-derived rhinitis, vasomotor rhinitis or non-allergic rhinitis during therapy.
  • 2)Patients who have developed asthmatic attack within 5 years before the pre-treatment observation visit.
  • 3)Patients who have received specific immunotherapy for cedar pollinosis in history.

研究者

相似试验